Literature DB >> 23876852

Eradication of gastric cancer is now both possible and practical.

Akiko Shiotani1, Putao Cen, David Y Graham.   

Abstract

In 1994, Helicobacter pylori was declared a human carcinogen. Evidence has now accumulated to show that at least 95% of gastric cancers are etiologically related to H. pylori. An extensive literature regarding atrophic gastritis and its effects on acid secretion, gastric microflora, and its tight association with gastric cancer has been rediscovered, confirmed, and expanded. Methods to stratify cancer risk based on endoscopic and histologic findings or serologic testing of pepsinogen levels and H. pylori testing have been developed producing practical primary and secondary gastric cancer prevention strategies. H. pylori eradication halts progressive mucosal damage. Cure of the infection in those with non-atrophic gastritis will essentially prevent subsequent development of gastric cancer. For all, the age-related progression in cancer risk is halted and likely reduced as eradication reduces or eliminates mucosal inflammation and reverses or reduces H. pylori-associated molecular events such aberrant activation-induced cytidine deaminase expression, double strand DNA breaks, impaired DNA mismatch repair and aberrant DNA methylation. Those who have developed atrophic gastritis/gastric atrophy however retain some residual risk for gastric cancer which is proportional to the extent and severity of atrophic gastritis. Primary and secondary cancer prevention starts with H. pylori eradication and cancer risk stratification to identify those at higher risk who should also be considered for secondary cancer prevention programs. Japan has embarked on population-wide H. pylori eradication coupled with surveillance targeted to those with significant remaining risk. We anticipate that countries with high gastric cancer burdens will follow their lead. We provide specific recommendations on instituting practical primary and secondary gastric cancer prevention programs as well identifying research needed to make elimination of gastric cancer both efficient and cost effective.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  AID; Atrophic gastritis; BRCA1; CDH1; CDKN2A; CI; Cancer screening; CpG; GI; Gastric cancer; H. pylori; Helicobacter pylori; IARC; International Agency for Research on Cancer; KLF5; Krüppel-like factor 5; MGMT; MLH1; Natural history; OLGA; Operative Link on Gastritis Assessment; Pepsinogen; Prevention; Primary prevention; RUNX3; Risk; Secondary prevention; Surveillance; VCP; activation-induced cytidine deaminase; breast cancer susceptibility gene 1; cadherin-1; confidence interval; cyclin-dependent kinase inhibitor 2A; cytosine-phosphate-guanine are regions of DNA; gastrointestinal; hMLH1; human mutL homolog 1; methylated-DNA–protein-cysteine methyltransferase; mutL homolog 1; runt-related transcription factor 3; valosin-containing protein

Mesh:

Year:  2013        PMID: 23876852     DOI: 10.1016/j.semcancer.2013.07.004

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  41 in total

1.  Changing the natural history of metachronous gastric cancer after H. pylori eradication.

Authors:  David Y Graham; Satoko Matsueda; Akiko Shiotani
Journal:  Jpn J Helicobacter Res       Date:  2015

Review 2.  Changing Trends in Stomach Cancer Throughout the World.

Authors:  Maya Balakrishnan; Rollin George; Ashish Sharma; David Y Graham
Journal:  Curr Gastroenterol Rep       Date:  2017-08

3.  Role of age in association between gastric cancer and Helicobacter pylori eradication in cases with intestinal metaplasia and dysplasia.

Authors:  Ali Kabir
Journal:  Gastric Cancer       Date:  2015-04-17       Impact factor: 7.370

4.  RE: Effects of helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups.

Authors:  David Y Graham; Masahiro Asaka
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

5.  RE: Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Response.

Authors:  Mitchell H Gail; Wei-Cheng You; Wen-Qing Li
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

6.  Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.

Authors:  Jason Y Park; Kerry B Dunbar; Midori Mitui; Christina A Arnold; Dora M Lam-Himlin; Mark A Valasek; Irene Thung; Chinemerem Okwara; Elizabeth Coss; Byron Cryer; Christopher D Doern
Journal:  Dig Dis Sci       Date:  2016-02-29       Impact factor: 3.199

7.  Time Trends in Helicobacter pylori Infection and Atrophic Gastritis Over 40 Years in Japan.

Authors:  Tomoari Kamada; Ken Haruma; Masanori Ito; Kazuhiko Inoue; Noriaki Manabe; Hiroshi Matsumoto; Hiroaki Kusunoki; Jiro Hata; Masaharu Yoshihara; Koji Sumii; Takashi Akiyama; Shinji Tanaka; Akiko Shiotani; David Y Graham
Journal:  Helicobacter       Date:  2015-01-07       Impact factor: 5.753

Review 8.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

9.  Age, period, and cohort effects on gastric cancer mortality.

Authors:  Constance Wang; Ann Weber; David Y Graham
Journal:  Dig Dis Sci       Date:  2014-10-02       Impact factor: 3.199

Review 10.  Genetic diversity, inbreeding and cancer.

Authors:  Beata Ujvari; Marcel Klaassen; Nynke Raven; Tracey Russell; Marion Vittecoq; Rodrigo Hamede; Frédéric Thomas; Thomas Madsen
Journal:  Proc Biol Sci       Date:  2018-03-28       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.